<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Laminin alpha2-deficient <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, called <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e>, is a rare, devastating <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disease</z:e> characterized by severe <z:hpo ids='HP_0001319'>neonatal hypotonia</z:hpo> ("<z:e sem="disease" ids="C0270971" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">floppy infant syndrome</z:e>"), <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo>, inability to stand or walk, <z:hpo ids='HP_0002098'>respiratory distress</z:hpo>, and premature <z:hpo ids='HP_0011420'>death</z:hpo> in early life </plain></SENT>
<SENT sid="1" pm="."><plain>Transgenic overexpression of the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> inhibitor protein BCL-2, or deletion of the proapoptotic Bax gene in a mouse model for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> prolongs survival and mitigates pathology, indicating that apoptotic events are involved in the pathology </plain></SENT>
<SENT sid="2" pm="."><plain>Here we demonstrate that the proapoptotic <z:chebi fb="0" ids="17138">glyceraldehyde-3-phosphate</z:chebi> dehydrogenase (GAPDH)-Siah1-CBP/p300-p53 pathway is activated in a mouse model for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, we show that omigapil, which inhibits GAPDH-Siah1-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, ameliorates several pathological hallmarks in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> mouse model </plain></SENT>
<SENT sid="4" pm="."><plain>Specifically, we demonstrate that treatment with omigapil inhibits <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in muscle, reduces body <z:hpo ids='HP_0001824'>weight loss</z:hpo> and skeletal deformation, increases locomotive activity, and protects from early mortality </plain></SENT>
<SENT sid="5" pm="."><plain>These data qualify omigapil, which is in late phase of clinical development for human use, as a drug candidate for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> </plain></SENT>
</text></document>